MarketLens

The GLP-1 Revolution: A Financial Game-Changer for Millions

5 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Is the GLP-1 Market Still a Blockbuster Opportunity for Investors

5 months ago

Is Shinhan Financial Group's "Value-Up +++" Plan a Game Changer for Investors

3 months ago

Is the GLP-1 Price War Escalating, and What Does it Mean for Eli Lilly

6 months ago

Is Netflix's Strategic Pivot a Game Changer for Investors

6 months ago

Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says

Bank of America's GLP-1 drug spending for employees surged from zero to over $250 million annually in about five years, CEO Brian Moynihan said, calling the expense a "good investment."

GLP

Stock News•1 months ago

Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients

Amgen's monthly weight loss drug candidate has six Phase 3 trials underway, signaling a direct challenge to Eli Lilly and Novo Nordisk's market dominance.

AMGN

Stock News•1 months ago

The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It

A $2 billion opportunity in large-volume body contouring and restoration is emerging, driven by GLP-1 weight-loss drug demand. Conexeu is developing solutions for this unclaimed aesthetics category.

GLP

Stock News•1 months ago

Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage

Weight loss ETFs could rally after Medicare greenlights GLP-1 coverage, expanding access to obesity drugs and offering diversified exposure to the market.

GLP